Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-76.0% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

TransCode Therapeutics Inc

RNAZ | $0.452 -1.72% -1.75% 91K

Professional, Scientific, and T...

(0.0% 1d) (-32.1% 1m) (-93.7% 1y) (0.0% 2d) (0.0% 3d) (-8.0% 7d) (-63.57% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 2,625,240
https://www.transcodetherapeutics.com
Sec Filling | Patents | 2021 employees

TransCode Therapeutics is an emerging RNA oncology company created to realize its belief that cancer can be defeated through the intelligent design of RNA therapeutics. This belief is based on a new approach to address what TransCode believes has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which TransCode believes has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. TransCode anticipates submitting an IND, in the second half of 2021 to support initiation of a Phase 0 clinical study with TTX-MC138.

cancer pancreatic glioblastoma

add to watch list Paper trade email alert is off

Recursion Pharmaceuticals Inc - Class A

RXRX | $7.94 3.12% 3.02% 7.1M

Professional, Scientific, and T...

(0.0% 1d) (-26.9% 1m) (48.9% 1y) (0.0% 2d) (1.3% 3d) (4.1% 7d) (29.52% volume)
Earnings Calendar: 2024-02-26
Market Cap: $ 1,803,518,604
https://www.recursionpharma.com
Sec Filling | Patents | n/a employees

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.

drug discovery machine learning

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.07 0.0% 180K

Professional, Scientific, and T...

(0.0% 1d) (-29.6% 1m) (-27.7% 1y) (0.0% 2d) (-7.0% 3d) (-1.8% 7d) (-46.76% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,189,387
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off

Aerovate Therapeutics Inc

AVTE M | $21.27 -8.4% -9.17% 300K

Professional, Scientific, and T...

(0.0% 1d) (-13.8% 1m) (23.7% 1y) (0.0% 2d) (4.7% 3d) (5.3% 7d) (35.32% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 592,582,200
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

treatment

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.729 0.47% 0.47% 20K

Professional, Scientific, and T...

(0.0% 1d) (-27.7% 1m) (30.4% 1y) (0.0% 2d) (5.8% 3d) (5.8% 7d) (-58.52% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 5,005,931
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off